Anti-allergic effects of His-Ala-Gln tripeptide in vitro and in vivo | Zendy

Mamoru Tanaka | Zendy; Hiroyuki Watanabe | Zendy; Yoshinobu Yoshimoto | Zendy; Hana Kozai | Zendy; Takeaki Okamoto | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anti-allergic effects of His-Ala-Gln tripeptide in vitro and in vivo

Author(s) -

Mamoru Tanaka,

Hiroyuki Watanabe,

Yoshinobu Yoshimoto,

Hana Kozai,

Takeaki Okamoto

Publication year - 2016

Publication title -

bioscience biotechnology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.509

H-Index - 116

eISSN - 1347-6947

pISSN - 0916-8451

DOI - 10.1080/09168451.2016.1243984

Subject(s) - in vivo , tripeptide , in vitro , pharmacology , allergy , peptide , chemistry , immunoglobulin e , medicine , immunology , biochemistry , biology , antibody , microbiology and biotechnology

We examined the inhibitory effects of HAQ (His-Ala-Gln) peptide on type-1 allergy in vitro and in vivo. HAQ peptide inhibited β-hexosaminidase release and intracellular Ca2+ levels of rat basophilic leukemia RBL-2H3 cells. Oral administration of a HAQ peptide-added diet (1 mg/mouse/administration) to C3H/HeJ mice for 14 days led to significant suppression of allergic symptoms, but did not reduce allergen-specific IgE or IgG1.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research